View the Sanofi and IDC symposia
Two of the symposia of our Conference can be viewed online without needing an access key:
- 10 years of evidence using high dose influenza vaccine in people age 65 and older, a Sanofi Pasteur Symposium chaired by Rosalind Hollingsworth.
- Influenza in persons living with diabetes. Pathogenesis and prevention, an Influenza Diabetes Community Symposium chaired by Marco Goeijenbier and Xavier Cos.
Enjoy!
Six benefits of our #ESWI2020 virtual edition
1. Increased reach
Extension of your own personal reach to audiences globally. We are building a VIRTUAL SCIENTIFIC KNOWLEDGE CENTER ON INFLUENZA, RSV DISEASE AND COVID-19 that stays on line till January 2021. The organisers will promote the virtual Platform and content by sending out monthly e-newsletters – highlighting specific research and / or topics.
2. More interaction
Research shows that a virtual conference will generate far more interaction with an online audience than in a traditional setting. Visitors will be able to participate during sessions with posts or chats and connect 1-to-1 with speakers before, during and after the session or event.
3. Knowledge transfer
More time and extended availability of research data increases knowledge transfer. Online events on a specific topic are a very compact and clear source of information, driving your scientific work to the next level.
4. Limited travel
On average conference visitors will spend 1 to 3 days traveling from and to event locations. We save some time by making our Conference available on line.
5. Flexibility
You can join from wherever in the world at your own pace, with access whenever you want. You develop your own conference experience.
6. Sustainable
It is almost a no brainer. The reduction of the entire carbon footprint when staff and visitors do not have to travel to a venue is huge!
Why should influenza and RSV experts meet?
1. From a clinical perspective
- Influenza and RSV cause very similar respiratory disease
- Influenza and RSV hit the extremes of age the hardest (children and the elderly)
2. From a pathogenesis perspective
- Clear overlaps as well as clear differences
- Resulting in major implications for intervention strategies
3. From an intervention strategies perspective (vaccines, antivirals and biological response modifiers)
- Intervention strategies for influenza are improving and emerging
- New intervention strategies for RSV are emerging
- Prospects for:
- Combined diagnostics/hospital management strategies
- Combined vaccination strategies
- Biological response modifiers: similar pathogeneses resulting in similar approaches
4. From a policy perspective
- Reimbursement policies for both influenza and RSV intervention strategies are crucial
Eswi's partner organizations





















